Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

Drug Manufacturers - Specialty & Generic • Healthcare • Ann Arbor, MI, United States • ESPR (NGM)

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Wikipedia

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Why Is Esperion Therapeutics Stock Sinking Premarket Today? - MSN
MSN • Jan 4
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Yahoo Finance
Yahoo Finance • Dec 9
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
MarketBeat • Jan 3
Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability - Seeking Alpha
Seeking Alpha • Nov 10
Esperion’s Stock Surge: Opportunity Knocks?​ - StocksToTrade
StocksToTrade • Dec 11

Other Drug Manufacturers - Specialty & Generic Companies

View All →
Elanco Animal Health Inc logo Elanco Animal Health Inc.
1 layoff tracked
$11.23B market cap
Zoetis Inc. logo Zoetis Inc.
$55.83B market cap
Galderma Group AG/ADR logo Galderma Group AG
$49.28B market cap
TAKEDA PHARMACEUTICAL CO LTD logo Takeda Pharmaceutical Co. Ltd.
$47.02B market cap
Haleon plc logo Haleon PLC
$44.93B market cap
TEVA PHARMACEUTICAL INDUSTRIES LTD logo TEVA Pharmaceutical Industries Ltd.
$32.82B market cap

Frequently Asked Questions

Has Esperion Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Esperion Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Esperion Therapeutics, Inc. have?
Esperion Therapeutics, Inc. has approximately 304 employees.
What industry is Esperion Therapeutics, Inc. in?
Esperion Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.
Is Esperion Therapeutics, Inc. a publicly traded company?
Yes, Esperion Therapeutics, Inc. is publicly traded under the ticker symbol ESPR on the NGM. The company has a market capitalization of approximately $0.94 billion.
Where is Esperion Therapeutics, Inc. headquartered?
Esperion Therapeutics, Inc. is headquartered in Ann Arbor, MI, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.